Literature DB >> 16836062

[Gastric cancer--risk factors and medical therapy].

J Harder1, O G Opitz.   

Abstract

Gastric cancer is the fourth common cancer worldwide and the second leading cause of cancer related deaths. Although the incidence of gastric cancer is declining, gastric cancer will remain a serious medical problem due to its high mortality rates. In contrast, cancer of the gastroesophageal junction is the most increasing neoplasm in the western world. Unfortunately, the vast majority of gastric cancer is diagnosed at an advanced stage, associated with a poor prognosis where the therapeutic options are limited. Over the past 15 years advances have been made in the knowledge of risk factors as well as the pathogenesis of gastric cancer. As the most important exogenous risk factor Helicobacter pylori was categorized as a class I carcinogen by the WHO. Additionally, genetic changes associated with the risk of gastric cancer have been defined. Progress, although slow, has also been made in the non-surgical therapy of gastric cancer due to multimodal therapeutic strategies. All these advances could lead to a better identification of patients being at risk of developing gastric cancer. Furthermore, new neoadjuvant and adjuvant therapy regimes as well as targeted therapeutic approaches in the future could lead to a better prognosis of gastric cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16836062     DOI: 10.1024/0369-8394.95.25.1021

Source DB:  PubMed          Journal:  Praxis (Bern 1994)        ISSN: 1661-8157


  3 in total

1.  Zic1 Promoter Hypermethylation in Plasma DNA Is a Potential Biomarker for Gastric Cancer and Intraepithelial Neoplasia.

Authors:  Xueqin Chen; Zhenghua Lin; Meng Xue; Jianmin Si; Shujie Chen
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

2.  G protein subunit α q regulates gastric cancer growth via the p53/p21 and MEK/ERK pathways.

Authors:  Yizhuo Wang; Huijie Xiao; Haitao Wu; Cheng Yao; Hua He; Chang Wang; Wei Li
Journal:  Oncol Rep       Date:  2017-03-13       Impact factor: 3.906

3.  Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B.

Authors:  Guoqing Pan; Zhu Zhu; Jian Huang; Chenggang Yang; Ying Yang; Yingxia Wang; Xiaoyu Tuo; Guomiao Su; Xiangling Zhang; Zhi Yang; Tao Liu
Journal:  Dig Dis Sci       Date:  2013-05-10       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.